Invivyd (NASDAQ:IVVD) Upgraded at Zacks Research

Zacks Research upgraded shares of Invivyd (NASDAQ:IVVD) from a strong sell rating to a hold rating in a research report released on Thursday,Zacks.com reports.

Several other analysts have also commented on the company. D. Boral Capital boosted their price target on Invivyd from $1.00 to $2.00 and gave the company a “buy” rating in a research note on Monday, October 6th. Weiss Ratings restated a “sell (e+)” rating on shares of Invivyd in a research note on Friday, October 31st. Cantor Fitzgerald initiated coverage on shares of Invivyd in a report on Monday, October 6th. They issued an “overweight” rating and a $10.00 target price on the stock. Finally, HC Wainwright increased their target price on shares of Invivyd from $5.00 to $10.00 and gave the stock a “buy” rating in a research report on Friday, October 31st. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $6.39.

Invivyd Stock Up 32.8%

NASDAQ:IVVD opened at $2.35 on Thursday. Invivyd has a 12-month low of $0.35 and a 12-month high of $2.76. The firm has a market capitalization of $547.83 million, a PE ratio of -5.00 and a beta of 0.64. The firm has a 50-day moving average price of $1.56 and a 200 day moving average price of $1.05.

Invivyd (NASDAQ:IVVD) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.01). Invivyd had a negative net margin of 119.63% and a negative return on equity of 92.97%. The company had revenue of $13.13 million for the quarter, compared to analyst estimates of $12.00 million. On average, research analysts expect that Invivyd will post -1.64 EPS for the current year.

Insider Activity

In related news, insider Jill Andersen sold 49,402 shares of the company’s stock in a transaction dated Tuesday, August 19th. The shares were sold at an average price of $0.57, for a total transaction of $28,159.14. Following the transaction, the insider owned 84,446 shares in the company, valued at $48,134.22. This represents a 36.91% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold 277,654 shares of company stock valued at $167,215 over the last three months. Insiders own 25.40% of the company’s stock.

Hedge Funds Weigh In On Invivyd

Institutional investors have recently modified their holdings of the stock. XTX Topco Ltd acquired a new position in shares of Invivyd during the first quarter worth approximately $66,000. Invesco Ltd. raised its position in Invivyd by 190.6% in the 1st quarter. Invesco Ltd. now owns 108,999 shares of the company’s stock worth $66,000 after purchasing an additional 71,485 shares during the last quarter. Nuveen LLC acquired a new position in Invivyd during the 1st quarter worth $65,000. AQR Capital Management LLC boosted its position in Invivyd by 2,051.0% in the 1st quarter. AQR Capital Management LLC now owns 410,711 shares of the company’s stock valued at $249,000 after buying an additional 391,617 shares during the last quarter. Finally, Vanguard Personalized Indexing Management LLC boosted its position in Invivyd by 238.6% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 39,941 shares of the company’s stock valued at $29,000 after buying an additional 28,146 shares during the last quarter. 70.36% of the stock is owned by institutional investors.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.